

# JÃ¼rgen Floege

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12137939/publications.pdf>

Version: 2024-02-01

361  
papers

28,173  
citations

4146

87  
h-index

6996

154  
g-index

368  
all docs

368  
docs citations

368  
times ranked

20243  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 551-561.   | 0.7  | 10        |
| 2  | Combining phosphate binder therapy with vitamin K2 inhibits vascular calcification in an experimental animal model of kidney failure. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 652-662.                                | 0.7  | 11        |
| 3  | Advanced Tertiary Lymphoid Tissues in Protocol Biopsies are Associated with Progressive Graft Dysfunction in Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 186-200.           | 6.1  | 25        |
| 4  | Platelet Abnormalities in CKD and Their Implications for Antiplatelet Therapy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 155-170.   | 4.5  | 24        |
| 5  | The management of membranous nephropathy – an update. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1033-1042.  | 0.7  | 7         |
| 6  | Deep learning-based classification of kidney transplant pathology: a retrospective, multicentre, proof-of-concept study. <i>The Lancet Digital Health</i> , 2022, 4, e18-e26.  | 12.3 | 43        |
| 7  | Altered vitamin K biodistribution and metabolism in experimental and human chronic kidney disease. <i>Kidney International</i> , 2022, 101, 338-348.   | 5.2  | 21        |
| 8  | CD153/CD30 signaling promotes age-dependent tertiary lymphoid tissue expansion and kidney injury. <i>Journal of Clinical Investigation</i> , 2022, 132, .  | 8.2  | 36        |
| 9  | Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 291-303.  | 6.1  | 10        |
| 10 | SARS-CoV-2 infects the human kidney and drives fibrosis in kidney organoids. <i>Cell Stem Cell</i> , 2022, 29, 217-231.e8.   | 11.1 | 146       |
| 11 | Authors' Reply: Advanced Tertiary Lymphoid Tissues in Kidney Transplant Recipients: Addressing Additional Methods To Detect Intragraft B Cells. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, , ASN.2021121588. | 6.1  | 1         |
| 12 | Educational Attainment Is Associated With Kidney and Cardiovascular Outcomes in the German CKD (GCKD) Cohort. <i>Kidney International Reports</i> , 2022, 7, 1004-1015.  | 0.8  | 8         |
| 13 | Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1400-1410.                             | 0.7  | 21        |
| 14 | Influence of rivaroxaban compared to vitamin K antagonist treatment upon development of cardiovascular calcification in patients with atrial fibrillation and/or pulmonary embolism. <i>Clinical Cardiology</i> , 2022, 45, 352-358. | 1.8  | 2         |
| 15 | Heart-Type Fatty Acid Binding Protein, Cardiovascular Outcomes, and Death: Findings From the German CKD Cohort Study. <i>American Journal of Kidney Diseases</i> , 2022, , .   | 1.9  | 0         |
| 16 | A Core Outcome Set for Trials in Glomerular Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 53-64.   | 4.5  | 4         |
| 17 | Current kidney function parameters overestimate kidney tissue repair in reversible experimental kidney disease. <i>Kidney International</i> , 2022, 102, 307-320.  | 5.2  | 14        |
| 18 | MO066: The Role of Platelet-Derived Growth Factor in Focal Segmental Glomerulosclerosis. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .  | 0.7  | 0         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | MO056: Alteration of Glycocalyx on Endothelium of Peritubular Capillaries in CKD. Nephrology Dialysis Transplantation, 2022, 37, .   | 0.7 | 0         |
| 20 | Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy. JAMA - Journal of the American Medical Association, 2022, 327, 1888.                         | 7.4 | 103       |
| 21 | Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure. ESC Heart Failure, 2022, 9, 2233-2238.  | 3.1 | 15        |
| 22 | International Physicians Delphi Survey: Managing Patients With IgA Nephropathy. Kidney International Reports, 2022, 7, 2076-2080.  | 0.8 | 1         |
| 23 | How I Treat IgA Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 1243-1246.   | 4.5 | 8         |
| 24 | Assessing prognosis in IgA nephropathy. Kidney International, 2022, 102, 22-24.  | 5.2 | 8         |
| 25 | Deep Learning-Based Segmentation and Quantification in Experimental Kidney Histopathology. Journal of the American Society of Nephrology: JASN, 2021, 32, 52-68.   | 6.1 | 93        |
| 26 | WNT- $\beta$ -catenin signalling " a versatile player in kidney injury and repair. Nature Reviews Nephrology, 2021, 17, 172-184.   | 9.6 | 200       |
| 27 | Hyperuricemia and progression of chronic kidney disease: to treat or not to treat?. Kidney International, 2021, 99, 14-16.   | 5.2 | 7         |
| 28 | Evidence of an intestinal phosphate transporter alternative to type IIb sodium-dependent phosphate transporter in rats with chronic kidney disease. Nephrology Dialysis Transplantation, 2021, 36, 68-75.        | 0.7 | 14        |
| 29 | Low adherence to CKD-specific dietary recommendations associates with impaired kidney function, dyslipidemia, and inflammation. European Journal of Clinical Nutrition, 2021, 75, 1389-1397.                     | 2.9 | 14        |
| 30 | Dapagliflozin, advanced chronic kidney disease, and mortality: new insights from the DAPA-CKD trial. European Heart Journal, 2021, 42, 1228-1230.  | 2.2 | 15        |
| 31 | Cardiovascular Disease in Chronic Kidney Disease. Circulation, 2021, 143, 1157-1172.   | 1.6 | 680       |
| 32 | Effects of Perfusion Pressures on Podocyte Loss in the Isolated Perfused Mouse Kidney.. Cellular Physiology and Biochemistry, 2021, 55, 1-12.  | 1.6 | 3         |
| 33 | The STARMEN trial: rethinking calcineurin inhibitor therapy in membranous nephropathy. Kidney International, 2021, 99, 811-813.  | 5.2 | 1         |
| 34 | Key metalloproteinase-mediated pathways in the kidney. Nature Reviews Nephrology, 2021, 17, 513-527.   | 9.6 | 46        |
| 35 | Parathyroid hormone oxidation in chronic kidney disease: clinical relevance?. Kidney International, 2021, 99, 1070-1072.   | 5.2 | 1         |
| 36 | MO326CORTICOSTEROIDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF REPORTED ADVERSE EVENTS IN RANDOMISED CONTROLLED TRIALS. Nephrology Dialysis Transplantation, 2021, 36, . | 0.7 | 0         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 37 | MO442ACUTE ADVERSE EFFECTS OF LOW POTASSIUM ON HEART AND KIDNEY*. Nephrology Dialysis Transplantation, 2021, 36, .   | 0.7  | 0         |
| 38 | FC 079HIGH SERUM PHOSPHATE, A NOVEL POTENTIAL RISK FACTOR FOR BONE FRAGILITY FRACTURES IN THE COSMOS STUDY. Nephrology Dialysis Transplantation, 2021, 36, .   | 0.7  | 0         |
| 39 | MO331LINEAGE TRACING OF REGENERATING PROXIMAL TUBULE CELLS (STC) BY SINGLE CELL PROFILING IN ACUTE KIDNEY INJURY. Nephrology Dialysis Transplantation, 2021, 36, .   | 0.7  | 0         |
| 40 | Non-invasive molecular imaging of kidney diseases. Nature Reviews Nephrology, 2021, 17, 688-703.   | 9.6  | 26        |
| 41 | Precision medicine in immunoglobulin A nephropathy: still a journey ahead. Nephrology Dialysis Transplantation, 2021, 36, 24-30.   | 0.7  | 4         |
| 42 | Cardiovascular disease in patients with chronic kidney disease. Herz, 2021, 46, 205-205.   | 1.1  | 8         |
| 43 | SGLT-2 inhibition in IgA nephropathy: the new standard of care?. Kidney International, 2021, 100, 24-26.   | 5.2  | 33        |
| 44 | Vitamin K and cardiovascular complications in chronic kidney disease patients. Kidney International, 2021, 100, 1023-1036.   | 5.2  | 19        |
| 45 | Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis. American Journal of Kidney Diseases, 2021, 78, 340-349.e1. | 1.9  | 28        |
| 46 | Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target. Kidney International, 2021, 100, 1199-1207.  | 5.2  | 23        |
| 47 | Current treatment of IgA nephropathy. Seminars in Immunopathology, 2021, 43, 717-728.  | 6.1  | 52        |
| 48 | KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International, 2021, 100, S1-S276.  | 5.2  | 782       |
| 49 | Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney International, 2021, 100, 753-779.   | 5.2  | 325       |
| 50 | Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease. Kidney International, 2021, 100, 881-893.  | 5.2  | 7         |
| 51 | Decoding myofibroblast origins in human kidney fibrosis. Nature, 2021, 589, 281-286.   | 27.8 | 380       |
| 52 | Monitoring transcellular fluid shifts during episodes of intradialytic hypotension using bioimpedance spectroscopy. CKJ: Clinical Kidney Journal, 2021, 14, 149-155.   | 2.9  | 6         |
| 53 | A focus group study of self-management in patients with glomerular disease.. Kidney International Reports, 2021, 7, 56-67.   | 0.8  | 2         |
| 54 | IgA nephropathy: a perspective for 2021. Seminars in Immunopathology, 2021, 43, 625-626.   | 6.1  | 5         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Survival with low- and high-flux dialysis. CKJ: Clinical Kidney Journal, 2021, 14, 1915-1923.   | 2.9 | 0         |
| 56 | Survival on four compared with three times per week haemodialysis in high ultrafiltration patients: an observational study. CKJ: Clinical Kidney Journal, 2021, 14, 665-672.  | 2.9 | 5         |
| 57 | The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics. American Journal of Nephrology, 2021, 52, 827-836.   | 3.1 | 15        |
| 58 | Rationale and design of XARENO: XA inhibition in RENal patients with non-valvular atrial fibrillation. Observational registry. Kardiologia Polska, 2021, 79, 1265-1267.   | 0.6 | 4         |
| 59 | New Aspects of Kidney Fibrosisâ€œFrom Mechanisms of Injury to Modulation of Disease. Frontiers in Medicine, 2021, 8, 814497.  | 2.6 | 21        |
| 60 | A Hypercaloric Diet Induces Early Podocyte Damage in Aged, Non-Diabetic Rats. Cellular Physiology and Biochemistry, 2021, 55, 96-112.   | 1.6 | 0         |
| 61 | Magnesium but not nicotinamide prevents vascular calcification in experimental uraemia. Nephrology Dialysis Transplantation, 2020, 35, 65-73.   | 0.7 | 23        |
| 62 | Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update. Nephrology Dialysis Transplantation, 2020, 35, 1002-1009. | 0.7 | 66        |
| 63 | Association of changes in bone mineral parameters with mortality in haemodialysis patients: insights from the ARO cohort. Nephrology Dialysis Transplantation, 2020, 35, 478-487.   | 0.7 | 19        |
| 64 | A collagen-binding protein enables molecular imaging of kidney fibrosis inÂvivo. Kidney International, 2020, 97, 609-614.   | 5.2 | 34        |
| 65 | The YB-1:Notch-3 axis modulates immune cell responses and organ damage in systemic lupus erythematosus. Kidney International, 2020, 97, 289-303.  | 5.2 | 18        |
| 66 | Epicardial fat, cardiovascular risk factors and calcifications in patients with chronic kidney disease. CKJ: Clinical Kidney Journal, 2020, 13, 571-579.  | 2.9 | 8         |
| 67 | Cinacalcet-induced hypocalcemia in a cohort of European haemodialysis patients: predictors, therapeutic approaches and outcomes. Journal of Nephrology, 2020, 33, 803-816.  | 2.0 | 8         |
| 68 | Phosphate binders in chronic kidney disease: an updated narrative review of recent data. Journal of Nephrology, 2020, 33, 497-508.  | 2.0 | 33        |
| 69 | The nucleic acid binding protein YB-1â€œcontrolled expression of CXCL-1 modulates kidney damage inÂliver fibrosis. Kidney International, 2020, 97, 741-752.   | 5.2 | 13        |
| 70 | A Functional Landscape of CKD Entities From Public Transcriptomic Data. Kidney International Reports, 2020, 5, 211-224.   | 0.8 | 14        |
| 71 | Association Between Dietary Patterns and Kidney Function in Patients With Chronic Kidney Disease: A Cross-Sectional Analysis of the German Chronic Kidney Disease Study. , 2020, 30, 296-304.                                 |     | 23        |
| 72 | Sodium thiosulphate and progression of vascular calcification in end-stage renal disease patients: a double-blind, randomized, placebo-controlled study. Nephrology Dialysis Transplantation, 2020, 35, 162-169.              | 0.7 | 35        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Mineral and bone disorder in chronic kidney disease: pioneering studies. <i>Kidney International</i> , 2020, 98, 807-811.   | 5.2 | 4         |
| 74 | Uremic Toxins Affecting Cardiovascular Calcification: A Systematic Review. <i>Cells</i> , 2020, 9, 2428.  | 4.1 | 12        |
| 75 | Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy. <i>Kidney International Reports</i> , 2020, 5, 2032-2041.  | 0.8 | 84        |
| 76 | P0794A REAL-WORLD OBSERVATIONAL STUDY OF ETELCALCETIDE USE IN HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM IN EUROPE. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .                              | 0.7 | 0         |
| 77 | Single versus dual blockade of the renin-angiotensin system in patients with IgA nephropathy. <i>Journal of Nephrology</i> , 2020, 33, 1231-1239.   | 2.0 | 13        |
| 78 | MicroRNAs in Chronic Kidney Disease: Four Candidates for Clinical Application. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6547.   | 4.1 | 42        |
| 79 | Why Target the Gut to Treat IgA Nephropathy?. <i>Kidney International Reports</i> , 2020, 5, 1620-1624.   | 0.8 | 37        |
| 80 | Cardiovascular complications of chronic kidney disease: pioneering studies. <i>Kidney International</i> , 2020, 98, 522-526.  | 5.2 | 9         |
| 81 | Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 673-684.                                      | 4.5 | 66        |
| 82 | Developmental stages of tertiary lymphoid tissue reflect local injury and inflammation in mouse and human kidneys. <i>Kidney International</i> , 2020, 98, 448-463.   | 5.2 | 50        |
| 83 | Hospitalization and mortality following non-attendance for hemodialysis according to dialysis day of the week: a European cohort study. <i>BMC Nephrology</i> , 2020, 21, 218.  | 1.8 | 9         |
| 84 | Cardiac Remodeling in Chronic Kidney Disease. <i>Toxins</i> , 2020, 12, 161.  | 3.4 | 81        |
| 85 | P1394ASSOCIATION BETWEEN PARATHYROID HORMONE AND MORTALITY IN HAEMODIALYSIS: THE DIABETES MAKES THE DIFFERENCE. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .  | 0.7 | 0         |
| 86 | Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study. <i>Nephron</i> , 2020, 144, 428-439.                       | 1.8 | 2         |
| 87 | Dysregulated mesenchymal PDGFR <sup>hi</sup> drives kidney fibrosis. <i>EMBO Molecular Medicine</i> , 2020, 12, e11021.   | 6.9 | 41        |
| 88 | Cardiovascular disease in patients with chronic kidney disease. <i>Herz</i> , 2020, 45, 122-128.  | 1.1 | 13        |
| 89 | Iron kinetics following treatment with sucroferric oxyhydroxide or ferric citrate in healthy rats and models of anaemia, iron overload or inflammation. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 946-954. | 0.7 | 3         |
| 90 | After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. <i>Kidney International</i> , 2020, 98, 1044-1052.                             | 5.2 | 103       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | Recommendations for the management of patients with immune-mediated kidney disease during the severe acute respiratory syndrome coronavirus 2 pandemic. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 920-925.                       | 0.7 | 14        |
| 92  | Management and treatment of glomerular diseases (part 1): conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. <i>Nephrology (Saint-Petersburg)</i> , 2020, 24, 22-41.                              | 0.4 | 10        |
| 93  | Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney diseaseâ€™mineral bone disorder parameters in dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1163-1170.                              | 0.7 | 28        |
| 94  | Serum phosphate optimal timing and range associated with patients survival in haemodialysis: the COSMOS study. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 673-681.  | 0.7 | 23        |
| 95  | Speckle Tracking Echocardiography and All-Cause and Cardiovascular Mortality Risk in Chronic Kidney Disease Patients. <i>Kidney and Blood Pressure Research</i> , 2019, 44, 690-703.  | 2.0 | 9         |
| 96  | A new tool to predict the risk of progression in IgA nephropathy. <i>Kidney International</i> , 2019, 96, 808-809.  | 5.2 | 3         |
| 97  | Evaluation of Electrocardiographic Parameters Predicting Cardiovascular Events in Patients with End-Stage Renal Disease before and after Transplantation. <i>Kidney and Blood Pressure Research</i> , 2019, 44, 615-627.                      | 2.0 | 3         |
| 98  | High-fat diet-induced obesity causes an inflammatory microenvironment in the kidneys of aging Long-Evans rats. <i>Journal of Inflammation</i> , 2019, 16, 14.   | 3.4 | 21        |
| 99  | Cre recombinase toxicity in podocytes: a novel genetic model for FSGS in adolescent mice. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 317, F1375-F1382.  | 2.7 | 4         |
| 100 | GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1735-1745. | 6.1 | 163       |
| 101 | Non-invasive evaluation of coronary heart disease in patients with chronic kidney disease using photoplethysmography. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 538-545.  | 2.9 | 13        |
| 102 | A Novel Role for GATA3 in Mesangial Cells in Glomerular Development and Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1641-1658.   | 6.1 | 31        |
| 103 | Fatal Attraction: Immunoglobulin A and the Glomerular Mesangium. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1139-1141.  | 6.1 | 2         |
| 104 | Standardized Outcomes in Nephrologyâ€™Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease. <i>Kidney International</i> , 2019, 95, 1280-1283.  | 5.2 | 20        |
| 105 | Trends of renal diseases in Germany: review of a regional renal biopsy database from 1990 to 2013. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 795-800.   | 2.9 | 17        |
| 106 | Antimalarials in IgA Nephropathy: Did Our Supportive Therapy Armamentarium Just Increase?. <i>American Journal of Kidney Diseases</i> , 2019, 74, 6-8.  | 1.9 | 6         |
| 107 | Novel 3D analysis using optical tissue clearing documents the evolution of murine rapidly progressive glomerulonephritis. <i>Kidney International</i> , 2019, 96, 505-516.  | 5.2 | 35        |
| 108 | Disruption of CUL3-mediated ubiquitination causes proximal tubule injury and kidney fibrosis. <i>Scientific Reports</i> , 2019, 9, 4596.  | 3.3 | 20        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 109 | Big science and big data in nephrology. <i>Kidney International</i> , 2019, 95, 1326-1337.  | 5.2  | 56        |
| 110 | Novel parietal epithelial cell subpopulations contribute to focal segmental glomerulosclerosis and glomerular tip lesions. <i>Kidney International</i> , 2019, 96, 80-93.                                 | 5.2  | 50        |
| 111 | Elastin imaging enables noninvasive staging and treatment monitoring of kidney fibrosis. <i>Science Translational Medicine</i> , 2019, 11, .  | 12.4 | 56        |
| 112 | Identification of platelet-derived growth factor C as a mediator of both renal fibrosis and hypertension. <i>Kidney International</i> , 2019, 95, 1103-1119.  | 5.2  | 14        |
| 113 | The authors reply. <i>Kidney International</i> , 2019, 96, 1422-1423.   | 5.2  | 0         |
| 114 | Left Ventricular Structure in Patients With Mild-to-Moderate CKDâ€”a Magnetic Resonance Imaging Study. <i>Kidney International Reports</i> , 2019, 4, 267-274.  | 0.8  | 7         |
| 115 | Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 268-280. | 5.2  | 198       |
| 116 | Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 281-295. | 5.2  | 135       |
| 117 | Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 469-481.                                    | 4.5  | 128       |
| 118 | Knee-to-knee bioimpedance measurements to monitor changes in extracellular fluid in haemodynamic-unstable patients during dialysis. <i>Journal of Electrical Bioimpedance</i> , 2019, 10, 55-62.          | 0.9  | 2         |
| 119 | IgA nephropathy: toward more specific diagnosis (and rescue of snails). <i>Kidney International</i> , 2018, 93, 542-544.  | 5.2  | 10        |
| 120 | Longâ€”term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients. <i>Hemodialysis International</i> , 2018, 22, 480-491.   | 0.9  | 10        |
| 121 | Inverse correlation between vascular endothelial growth factor back-filtration and capillary filtration pressures. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1514-1525.                      | 0.7  | 7         |
| 122 | Prognostic value of cardiovascular calcifications in hemodialysis patients: a longitudinal study. <i>International Urology and Nephrology</i> , 2018, 50, 939-946.  | 1.4  | 8         |
| 123 | Novel oral anticoagulants in patients with chronic kidney disease and atrial fibrillation. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1683-1689.  | 0.7  | 26        |
| 124 | Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial. <i>Kidney International</i> , 2018, 93, 1475-1482.                            | 5.2  | 41        |
| 125 | CTLA-4 Polymorphisms in Patients with IgA Nephropathy Correlate with Proteinuria. <i>Kidney and Blood Pressure Research</i> , 2018, 43, 360-366.  | 2.0  | 6         |
| 126 | The new SFB/TRR219 Research Centre. <i>European Heart Journal</i> , 2018, 39, 975-977.  | 2.2  | 11        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 127 | Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2018, 29, 317-325.   | 6.1 | 64        |
| 128 | Complement C5a receptors C5L2 and C5aR in renal fibrosis. American Journal of Physiology - Renal Physiology, 2018, 314, F35-F46.  | 2.7 | 24        |
| 129 | PDGF in organ fibrosis. Molecular Aspects of Medicine, 2018, 62, 44-62.   | 6.4 | 135       |
| 130 | Sclerostin deficiency modifies the development of CKD-MBD in mice. Bone, 2018, 107, 115-123.  | 2.9 | 20        |
| 131 | FP634HIGH ALL CAUSE AND CVD MORTALITY IN AN INCIDENT COHORT OF HEMODIALYSIS PATIENTS WITH LOW SERUM ALBUMIN AND INFLAMMATION. Nephrology Dialysis Transplantation, 2018, 33, i257-i257.   | 0.7 | 0         |
| 132 | FP088HETEROGENEITY AND CLINICAL RELEVANCE OF TERTIARY LYMPHOID TISSUES IN MURINE AND HUMAN KIDNEYS. Nephrology Dialysis Transplantation, 2018, 33, i77-i77.   | 0.7 | 0         |
| 133 | Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores). BMC Nephrology, 2018, 19, 328.  | 1.8 | 31        |
| 134 | SP406MAGNESIUM AND NICOTINAMIDE: COMPLEMENTARY STRATEGIES AGAINST CALCIFICATION IN EXPERIMENTAL UREMIA. Nephrology Dialysis Transplantation, 2018, 33, i484-i484.   | 0.7 | 0         |
| 135 | Dickkopf-3 (DKK3) in Urine Identifies Patients with Short-Term Risk of eGFR Loss. Journal of the American Society of Nephrology: JASN, 2018, 29, 2722-2733.   | 6.1 | 73        |
| 136 | Blood Pressure Pattern and Target Organ Damage in Patients With Chronic Kidney Disease. Hypertension, 2018, 72, 929-936.  | 2.7 | 29        |
| 137 | Urinary Biomarkers in the Prediction of Prognosis and Treatment Response in IgA Nephropathy. Kidney and Blood Pressure Research, 2018, 43, 1563-1572.   | 2.0 | 6         |
| 138 | IgA nephropathy: new insights into the role of complement. Kidney International, 2018, 94, 16-18.   | 5.2 | 31        |
| 139 | YB-1 increases glomerular, but decreases interstitial fibrosis in CNI-induced nephropathy. Clinical Immunology, 2018, 194, 67-74.   | 3.2 | 10        |
| 140 | Sucroferric oxyhydroxide for the treatment of hyperphosphatemia. Expert Opinion on Pharmacotherapy, 2018, 19, 1137-1148.  | 1.8 | 9         |
| 141 | Mechanisms of cardiovascular complications in chronic kidney disease: research focus of the Transregional Research Consortium SFB TRR219 of the University Hospital Aachen (RWTH) and the Saarland University. Clinical Research in Cardiology, 2018, 107, 120-126. | 3.3 | 25        |
| 142 | Magnesium Concentration in Dialysate. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1309-1310.   | 4.5 | 14        |
| 143 | Heterogeneity and clinical relevance of tertiary lymphoid tissues in murine and human kidney. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-3-24.  | 0.0 | 0         |
| 144 | Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide. Nephrology Dialysis Transplantation, 2017, 32, gfw242.  | 0.7 | 32        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 145 | Calcific uraemic arteriopathy (calciophylaxis): data from a large nationwide registry. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfv438.  | 0.7  | 113       |
| 146 | Skin Sodium Concentration Correlates with Left Ventricular Hypertrophy in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1867-1876.                                 | 6.1  | 157       |
| 147 | Calcification in arteriovenous fistula blood vessels may predict arteriovenous fistula failure: a 5-year follow-up study. <i>International Urology and Nephrology</i> , 2017, 49, 881-887.       | 1.4  | 9         |
| 148 | Treatment of Renal Fibrosisâ€”Turning Challenges into Opportunities. <i>Advances in Chronic Kidney Disease</i> , 2017, 24, 117-129.  | 1.4  | 109       |
| 149 | Investigations of Glucocorticoid Action in GN. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1408-1420.   | 6.1  | 46        |
| 150 | Slower Progress of Aortic Valve Calcification With Vitamin K Supplementation. <i>Circulation</i> , 2017, 135, 2081-2083.   | 1.6  | 114       |
| 151 | Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. <i>Lancet, The</i> , 2017, 389, 2117-2127. | 13.7 | 278       |
| 152 | Inflammation in IgA nephropathy. <i>Pediatric Nephrology</i> , 2017, 32, 2215-2224.  | 1.7  | 38        |
| 153 | Rituximab therapy for IgA nephropathy. <i>Nature Reviews Nephrology</i> , 2017, 13, 138-140.   | 9.6  | 4         |
| 154 | The longer the better: follow-up in seemingly â€˜benignâ€™ immunoglobulin A nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1777-1779.                                       | 0.7  | 3         |
| 155 | <sc>YB</sc>â€œ orchestrates onset and resolution of renal inflammation <i>via</i> <sc>IL</sc>10</i> gene regulation. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 3494-3505.    | 3.6  | 23        |
| 156 | Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 432.                             | 7.4  | 376       |
| 157 | Mucosal corticosteroid therapy of IgA nephropathy. <i>Kidney International</i> , 2017, 92, 278-280.  | 5.2  | 10        |
| 158 | Regardless of etiology, progressive renal disease causes ultrastructural and functional alterations of peritubular capillaries. <i>Kidney International</i> , 2017, 91, 70-85.                   | 5.2  | 122       |
| 159 | One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1918-1926.   | 0.7  | 21        |
| 160 | GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway. <i>PLoS Genetics</i> , 2017, 13, e1006609.   | 3.5  | 92        |
| 161 | Hypoglycemia following intravenous insulin plus glucose for hyperkalemia in patients with impaired renal function. <i>PLoS ONE</i> , 2017, 12, e0172961.   | 2.5  | 25        |
| 162 | SP329VITAMIN K ELIMINATES UREMIC POSTTRANSLATIONAL MODIFICATIONS OF THE GAMMA-GLUTAMYL CARBOXYLASE. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i200-i200.                            | 0.7  | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 163 | MO025NON-INVASIVE MOLECULAR IMAGING OF KIDNEY FIBROSIS. Nephrology Dialysis Transplantation, 2016, 31, i38-i38.  | 0.7 | 1         |
| 164 | TO032CONSEQUENCES AND FATE OF INTRARENAL CRYSTALS IN ADENINE NEPHROPATHY. Nephrology Dialysis Transplantation, 2016, 31, i74-i74.  | 0.7 | 1         |
| 165 | Cold Shock Proteins Mediate GN with Mesangioproliferation. Journal of the American Society of Nephrology: JASN, 2016, 27, 3678-3689.   | 6.1 | 10        |
| 166 | Therapeutic nuclear shuttling of YB-1 reduces renal damage and fibrosis. Kidney International, 2016, 90, 1226-1237.  | 5.2 | 32        |
| 167 | Contrast-enhanced CT imaging in patients with chronic kidney disease. Angiogenesis, 2016, 19, 525-535.   | 7.2 | 22        |
| 168 | ISN Nexus 2016 Symposia: Translational Immunology in Kidney Diseaseâ€”The Berlin Roadmap. Kidney International Reports, 2016, 1, 327-339.  | 0.8 | 1         |
| 169 | Cold shock protein YB-1 is involved in hypoxia-dependent gene transcription. Biochemical and Biophysical Research Communications, 2016, 478, 982-987.  | 2.1 | 20        |
| 170 | Con: STOP immunosuppression in IgA nephropathy. Nephrology Dialysis Transplantation, 2016, 31, 1771-1774.  | 0.7 | 9         |
| 171 | Anti-parathyroid treatment effectiveness and persistence in incident haemodialysis patients with secondary hyperparathyroidism. Nefrologia, 2016, 36, 164-175.   | 0.4 | 8         |
| 172 | Opponent's comments. Nephrology Dialysis Transplantation, 2016, 31, 1770-1770.   | 0.7 | 0         |
| 173 | Immunosuppressant-induced reduction of proteinuria in IgAN. Nature Reviews Nephrology, 2016, 12, 380-382.  | 9.6 | 2         |
| 174 | Gas6 protein: its role in cardiovascular calcification. BMC Nephrology, 2016, 17, 52.  | 1.8 | 18        |
| 175 | Cinacalcet, dialysate calcium concentration, and cardiovascular events in the <scp>EVOLVE</scp> trial. Hemodialysis International, 2016, 20, 421-431.  | 0.9 | 19        |
| 176 | Calcification Propensity and Survival among Renal Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2016, 27, 239-248.   | 6.1 | 115       |
| 177 | Immunosuppression in IgA nephropathy: how certain are we?. Kidney International, 2016, 89, 9-11.   | 5.2 | 4         |
| 178 | Phosphate binders in chronic kidney disease: a systematic review of recent data. Journal of Nephrology, 2016, 29, 329-340.   | 2.0 | 53        |
| 179 | Prognostic assessment of IgA nephropathy: how much does histology add?. Kidney International, 2016, 89, 19-21.   | 5.2 | 4         |
| 180 | Turnover of type III collagen reflects disease severity and is associated with progression and microinflammation in patients with IgA nephropathy. Nephrology Dialysis Transplantation, 2016, 31, 472-479. | 0.7 | 45        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 181 | Keratins are novel markers of renal epithelial cell injury. <i>Kidney International</i> , 2016, 89, 792-808.  | 5.2  | 72        |
| 182 | Lack of evidence does not justify neglect: how can we address unmet medical needs in calciphylaxis?. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1211-1219.  | 0.7  | 52        |
| 183 | Highlights of the 2015 ERA-EDTA Congressâ€”glomerular diseases. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, gfv433.  | 0.7  | 0         |
| 184 | Primary glomerulonephritides. <i>Lancet, The</i> , 2016, 387, 2036-2048.  | 13.7 | 202       |
| 185 | FGF-23 levels are associated with vascular calcification, but not with atherosclerosis, in hemodialysis patients. <i>International Urology and Nephrology</i> , 2016, 48, 609-617.  | 1.4  | 23        |
| 186 | The role of PDGF-D in healthy and fibrotic kidneys. <i>Kidney International</i> , 2016, 89, 848-861.  | 5.2  | 38        |
| 187 | The mucosaâ€”kidney axis in IgA nephropathy. <i>Nature Reviews Nephrology</i> , 2016, 12, 147-156.  | 9.6  | 101       |
| 188 | Vasculoprotective Effects of Dietary Cocoa Flavanols in Patients on Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 108-118.   | 4.5  | 46        |
| 189 | IL-6 Trans-Signaling Drives Murine Crescentic GN. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 132-142.   | 6.1  | 45        |
| 190 | Anti-parathyroid treatment effectiveness and persistence in incident haemodialysis patients with secondary hyperparathyroidism. <i>Nefrologia</i> , 2016, 36, 164-175.  | 0.4  | 11        |
| 191 | Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 539-546.                                   | 4.5  | 20        |
| 192 | Inflammation Modifies the Paradoxical Association between Body Mass Index and Mortality in Hemodialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1479-1486.                       | 6.1  | 91        |
| 193 | Quantitative Micro-Computed Tomography Imaging of Vascular Dysfunction in Progressive Kidney Diseases. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 520-532.                                    | 6.1  | 112       |
| 194 | Epicardial adipose tissue in long-term hemodialysis patients: its association with vascular calcification and long-term development. <i>Journal of Nephrology</i> , 2016, 29, 241-250.                                    | 2.0  | 13        |
| 195 | Vascular calcification in chronic kidney disease: an update. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 31-39.  | 0.7  | 203       |
| 196 | The vulnerable patient with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 382-390.   | 0.7  | 33        |
| 197 | Propensity score matching and persistence correction to reduce bias in comparative effectiveness: the effect of cinacalcet use on allâ€”cause mortality. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 738-747. | 1.9  | 17        |
| 198 | Anti-interleukin-6 therapy through application of a monogenic protein inhibitor via gene delivery. <i>Scientific Reports</i> , 2015, 5, 14685.  | 3.3  | 8         |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 199 | Diffusion-weighted MRI does not reflect kidney fibrosis in a rat model of fibrosis. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 42, 990-998.  | 3.4  | 44        |
| 200 | Increased Cerebral Water Content in Hemodialysis Patients. <i>PLoS ONE</i> , 2015, 10, e0122188.   | 2.5  | 22        |
| 201 | Platelet Hyperaggregability is Highly Prevalent in Patients With Chronic Kidney Disease. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2015, 21, 132-138.  | 1.7  | 18        |
| 202 | Klotho Deficiency and the Cardiomyopathy of Advanced CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1229-1231.  | 6.1  | 8         |
| 203 | The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 791-799.   | 4.5  | 75        |
| 204 | Glomerulonephritis triggered by a chronically infected left ventricular assist device. <i>Lancet</i> , The, 2015, 386, 2363-2364.  | 13.7 | 8         |
| 205 | Antagonism of Canonical Wnt/ $\beta$ -Catenin Signaling: Taking RAS Blockade to the Next Level?. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 3-5.   | 6.1  | 9         |
| 206 | Role of Platelet-Derived Growth Factor-CC in Capillary Rarefaction in Renal Fibrosis. <i>American Journal of Pathology</i> , 2015, 185, 2132-2142.   | 3.8  | 19        |
| 207 | Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis. <i>Circulation</i> , 2015, 132, 27-39.  | 1.6  | 259       |
| 208 | Challenging the use of warfarin in patients on dialysis with atrial fibrillation. <i>Nature Reviews Nephrology</i> , 2015, 11, 450-450.  | 9.6  | 5         |
| 209 | Disease burden and risk profile in referred patients with moderate chronic kidney disease: composition of the German Chronic Kidney Disease (GCKD) cohort. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 441-451. | 0.7  | 132       |
| 210 | Efficacy of corticosteroids in high-risk IgA nephropathy. <i>Nature Reviews Nephrology</i> , 2015, 11, 319-320.  | 9.6  | 4         |
| 211 | Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1037-1046.  | 0.7  | 109       |
| 212 | Moderator's view: Will 'modern' urine proteomics replace 'old-fashioned' renal biopsy?. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 538-540.  | 0.7  | 1         |
| 213 | Serum and urine markers of collagen degradation reflect renal fibrosis in experimental kidney diseases. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1112-1121.  | 0.7  | 53        |
| 214 | Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1542-1551.                       | 0.7  | 140       |
| 215 | Common histological patterns in glomerular epithelial cells in secondary focal segmental glomerulosclerosis. <i>Kidney International</i> , 2015, 88, 990-998.  | 5.2  | 57        |
| 216 | Nephrology research—the past, present and future. <i>Nature Reviews Nephrology</i> , 2015, 11, 677-687.  | 9.6  | 23        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 217 | Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. <i>New England Journal of Medicine</i> , 2015, 373, 2225-2236.  | 27.0 | 516       |
| 218 | The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 800-807.  | 4.5  | 107       |
| 219 | High cardiovascular event rates occur within the first weeks of starting hemodialysis. <i>Kidney International</i> , 2015, 88, 1117-1125.  | 5.2  | 96        |
| 220 | Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1466-1475.   | 6.1  | 163       |
| 221 | Magnesium in CKD: more than a calcification inhibitor?. <i>Journal of Nephrology</i> , 2015, 28, 269-277.  | 2.0  | 28        |
| 222 | High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 288-293.  | 0.7  | 111       |
| 223 | The Montreal Cognitive Assessment (MoCA) - A Sensitive Screening Instrument for Detecting Cognitive Impairment in Chronic Hemodialysis Patients. <i>PLoS ONE</i> , 2014, 9, e106700.   | 2.5  | 130       |
| 224 | Urinary Exosomes: A Novel Means to Non-Invasively Assess Changes in Renal Gene and Protein Expression. <i>PLoS ONE</i> , 2014, 9, e109631.   | 2.5  | 40        |
| 225 | Impaired vitamin K recycling in uremia is rescued by vitamin K supplementation. <i>Kidney International</i> , 2014, 86, 286-293.   | 5.2  | 78        |
| 226 | Vitamin K1 to slow vascular calcification in haemodialysis patients (VitaVasK trial): a rationale and study protocol. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1633-1638.  | 0.7  | 68        |
| 227 | Platelet-derived growth factors (PDGFs) in glomerular and tubulointerstitial fibrosis. <i>Kidney International Supplements</i> , 2014, 4, 65-69.   | 14.2 | 44        |
| 228 | Gp130-dependent signaling in the podocyte. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 307, F346-F355.  | 2.7  | 20        |
| 229 | A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. <i>Kidney International</i> , 2014, 86, 638-647.   | 5.2  | 154       |
| 230 | The Regenerative Potential of Parietal Epithelial Cells in Adult Mice. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 693-705.   | 6.1  | 96        |
| 231 | Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The Evaluation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial. <i>Journal of the American Heart Association</i> , 2014, 3, e001363. | 3.7  | 105       |
| 232 | Origin of regenerating tubular cells after acute kidney injury. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 1533-1538.   | 7.1  | 139       |
| 233 | Calcineurin-mediated YB-1 Dephosphorylation Regulates CCL5 Expression during Monocyte Differentiation. <i>Journal of Biological Chemistry</i> , 2014, 289, 21401-21412.  | 3.4  | 33        |
| 234 | Origin of Parietal Podocytes in Atubular Glomeruli Mapped by Lineage Tracing. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 129-141.  | 6.1  | 41        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 235 | New insights into the pathogenesis of IgA nephropathy. <i>Seminars in Immunopathology</i> , 2014, 36, 431-442.   | 6.1  | 53        |
| 236 | The ERA-EDTA database on recurrent glomerulonephritis following renal transplantation. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 15-21.   | 0.7  | 116       |
| 237 | Detection of Activated Parietal Epithelial Cells on the Glomerular Tuft Distinguishes Early Focal Segmental Glomerulosclerosis from Minimal Change Disease. <i>American Journal of Pathology</i> , 2014, 184, 3239-3248. | 3.8  | 81        |
| 238 | PDGF and the progression of renal disease. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, i45-i54.   | 0.7  | 82        |
| 239 | Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. <i>Nature Genetics</i> , 2014, 46, 1187-1196.   | 21.4 | 505       |
| 240 | Associations of FGF-23 and sKlotho with Cardiovascular Outcomes among Patients with CKD Stages 2â€“4. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1049-1058.                         | 4.5  | 126       |
| 241 | Management of Intraocular Hypertension During Hemodialysis by Intravenous Glucose Administration. <i>American Journal of Kidney Diseases</i> , 2014, 63, 500-502.  | 1.9  | 10        |
| 242 | Clinical Predictors of Individual Cognitive Fluctuations in Patients Undergoing Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2014, 64, 434-442.  | 1.9  | 50        |
| 243 | Chronische Niereninsuffizienz: StÃ¶rungen im Mineral- und Knochenstoffwechsel. , 2014, , 1-6.  |      | 0         |
| 244 | Primary glomerulonephritis: A review of important recent discoveries. <i>Kidney Research and Clinical Practice</i> , 2013, 32, 103-110.  | 2.2  | 12        |
| 245 | Treatment of IgA nephropathy and Henochâ€“SchÃ¶nlein nephritis. <i>Nature Reviews Nephrology</i> , 2013, 9, 320-327.   | 9.6  | 80        |
| 246 | COSMOS: the dialysis scenario of CKDâ€“MBD in Europe. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1922-1935.  | 0.7  | 79        |
| 247 | The Clinical Course of Treated Hyperparathyroidism Among Patients Receiving Hemodialysis and the Effect of Cinacalcet: The EVOLVE Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4834-4844.  | 3.6  | 63        |
| 248 | Recurrent IgA nephropathy in the renal allograft: not a benign condition. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1070-1073.  | 0.7  | 27        |
| 249 | Use of phosphate-binding agents is associated with a lower risk of mortality. <i>Kidney International</i> , 2013, 84, 998-1008.  | 5.2  | 136       |
| 250 | How effective and safe are antiplatelet agents in CKD?. <i>Nature Reviews Nephrology</i> , 2013, 9, 314-316.   | 9.6  | 4         |
| 251 | Management of hyperphosphataemia in chronic kidney disease--challenges and solutions. <i>CKJ: Clinical Kidney Journal</i> , 2013, 6, 128-136.  | 2.9  | 23        |
| 252 | Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 146-152.   | 0.7  | 64        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 253 | Albumin Is Recycled from the Primary Urine by Tubular Transcytosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 1966-1980.   | 6.1  | 115       |
| 254 | Osteogenesis of Heterotopically Transplanted Mesenchymal Stromal Cells in Rat Models of Chronic Kidney Disease. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 2523-2534.  | 2.8  | 26        |
| 255 | Geographic Differences in Genetic Susceptibility to IgA Nephropathy: GWAS Replication Study and Geospatial Risk Analysis. <i>PLoS Genetics</i> , 2012, 8, e1002765.   | 3.5  | 301       |
| 256 | Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2872-2879.  | 0.7  | 45        |
| 257 | Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2012, 367, 2482-2494.  | 27.0 | 805       |
| 258 | Subtotal Ablation of Parietal Epithelial Cells Induces Crescent Formation. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 629-640.  | 6.1  | 61        |
| 259 | Nanoparticle-Based Test Measures Overall Propensity for Calcification in Serum. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1744-1752.   | 6.1  | 275       |
| 260 | The renal (myo-)fibroblast: a heterogeneous group of cells. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3027-3036.   | 0.7  | 87        |
| 261 | A Novel, Dual Role of CCN3 in Experimental Glomerulonephritis. <i>American Journal of Pathology</i> , 2012, 180, 1979-1990.   | 3.8  | 25        |
| 262 | Notch $\epsilon$ 3 receptor activation drives inflammation and fibrosis following tubulointerstitial kidney injury. <i>Journal of Pathology</i> , 2012, 228, 286-299.   | 4.5  | 83        |
| 263 | Joint European League Against Rheumatism and European Renal Association $\text{\textasciitilde}$ European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1771-1782. | 0.9  | 868       |
| 264 | The platelet-derived growth factor system in renal disease: An emerging role of endogenous inhibitors. <i>European Journal of Cell Biology</i> , 2012, 91, 542-551.   | 3.6  | 24        |
| 265 | Effect of Vitamin K2 Supplementation on Functional Vitamin K Deficiency in Hemodialysis Patients: A Randomized Trial. <i>American Journal of Kidney Diseases</i> , 2012, 59, 186-195.   | 1.9  | 257       |
| 266 | Primary Cultures of Glomerular Parietal Epithelial Cells or Podocytes with Proven Origin. <i>PLoS ONE</i> , 2012, 7, e34907.  | 2.5  | 55        |
| 267 | Mesenchymal stem cells as a therapeutic approach to glomerular diseases: benefits and risks. <i>Kidney International Supplements</i> , 2011, 1, 68-73.  | 14.2 | 12        |
| 268 | Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1948-1955.  | 0.7  | 412       |
| 269 | Current Therapy for IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 1785-1794.  | 6.1  | 83        |
| 270 | Potential Risks of Stem Cell Therapies. , 2011, , 361-387.  |      | 1         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 271 | The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1327-1339. | 0.7 | 491       |
| 272 | Chronic kidney disease growth factors in renal fibrosis. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2011, 38, 441-450.   | 1.9 | 80        |
| 273 | The Pathogenesis of IgA Nephropathy: What Is New and How Does It Change Therapeutic Approaches?. <i>American Journal of Kidney Diseases</i> , 2011, 58, 992-1004.  | 1.9 | 85        |
| 274 | Effects and mechanisms of angiotensin II receptor blockade with telmisartan in a normotensive model of mesangioproliferative nephritis. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3131-3143.                    | 0.7 | 24        |
| 275 | Parietal Epithelial Cells Participate in the Formation of Sclerotic Lesions in Focal Segmental Glomerulosclerosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 1262-1274.                         | 6.1 | 186       |
| 276 | Circulating Nonphosphorylated Carboxylated Matrix Gla Protein Predicts Survival in ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 387-395.   | 6.1 | 207       |
| 277 | Electrical Forces Determine Glomerular Permeability. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 2053-2058.   | 6.1 | 61        |
| 278 | Ultrastructural Analysis of Vascular Calcifications in Uremia. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 689-696.   | 6.1 | 157       |
| 279 | Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1916-1923.         | 0.7 | 38        |
| 280 | Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2672-2679.                                    | 0.7 | 77        |
| 281 | ACEIs with or without corticosteroids in IgA nephropathy?. <i>Nature Reviews Nephrology</i> , 2010, 6, 252-254.  | 9.6 | 15        |
| 282 | Kidney calling lung and call back: how organs talk to each other. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 32-34.  | 0.7 | 13        |
| 283 | Analysis of Calcifications in Patients with Coral Reef Aorta. <i>Annals of Vascular Surgery</i> , 2010, 24, 408-414.   | 0.9 | 30        |
| 284 | Analyse des calcifications chez les patients ayant une atteinte coralliforme de lâ€™aorte. <i>Annales De Chirurgie Vasculaire</i> , 2010, 24, 446-453.   | 0.0 | 0         |
| 285 | Renal fibrosis: novel insights into mechanisms and therapeutic targets. <i>Nature Reviews Nephrology</i> , 2010, 6, 643-656.   | 9.6 | 517       |
| 286 | PDGF-C Mediates Glomerular Capillary Repair. <i>American Journal of Pathology</i> , 2010, 177, 58-69.  | 3.8 | 38        |
| 287 | Recruitment of Podocytes from Glomerular Parietal Epithelial Cells. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 333-343.  | 6.1 | 418       |
| 288 | Sodium thiosulfate in the treatment of calcific uremic arteriolopathy. <i>Nature Reviews Nephrology</i> , 2009, 5, 539-543.  | 9.6 | 98        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 289 | The SDF-1/CXCR4 Axis Is a Novel Driver of Vascular Development of the Glomerulus. Journal of the American Society of Nephrology: JASN, 2009, 20, 1659-1661.                                      | 6.1 | 13        |
| 290 | Tracing the Origin of Glomerular Extracapillary Lesions from Parietal Epithelial Cells. Journal of the American Society of Nephrology: JASN, 2009, 20, 2604-2615.                                | 6.1 | 218       |
| 291 | Association of fetuin-A levels with the progression of aortic valve calcification in non-dialyzed patients. European Heart Journal, 2009, 30, 2054-2061.   | 2.2 | 63        |
| 292 | Fetuin-A Protects against Atherosclerotic Calcification in CKD. Journal of the American Society of Nephrology: JASN, 2009, 20, 1264-1274.  | 6.1 | 160       |
| 293 | Kidney dendritic cell activation is required for progression of renal disease in a mouse model of glomerular injury. Journal of Clinical Investigation, 2009, 119, 1286-1297.                    | 8.2 | 180       |
| 294 | Cytokines and Growth Factors. , 2009, , 243-265.   |     | 0         |
| 295 | A New Look at Platelet-Derived Growth Factor in Renal Disease. Journal of the American Society of Nephrology: JASN, 2008, 19, 12-23.   | 6.1 | 272       |
| 296 | Immune Modulating Therapy for IgA Nephropathy: Rationale and Evidence. Seminars in Nephrology, 2008, 28, 38-47.  | 1.6 | 19        |
| 297 | Adynamic bone disease--bone and beyond. CKJ: Clinical Kidney Journal, 2008, 1, 135-147.  | 2.9 | 55        |
| 298 | Clinical Outcomes in Secondary Hyperparathyroidism and the Potential Role of Calcimimetics. CKJ: Clinical Kidney Journal, 2008, 1, i29-i35.  | 2.9 | 6         |
| 299 | PDGF-C Is a Proinflammatory Cytokine that Mediates Renal Interstitial Fibrosis. Journal of the American Society of Nephrology: JASN, 2008, 19, 281-289.  | 6.1 | 103       |
| 300 | Vascular access calcification predicts mortality in hemodialysis patients. Kidney International, 2008, 74, 1582-1587.  | 5.2 | 78        |
| 301 | Fetuin-A (AHSG) prevents extraosseous calcification induced by uraemia and phosphate challenge in mice. Nephrology Dialysis Transplantation, 2007, 22, 1537-1546.                                | 0.7 | 87        |
| 302 | Complement C5 Mediates Experimental Tubulointerstitial Fibrosis. Journal of the American Society of Nephrology: JASN, 2007, 18, 1508-1515.   | 6.1 | 100       |
| 303 | PDGF-D inhibition by CR002 ameliorates tubulointerstitial fibrosis following experimental glomerulonephritis. Nephrology Dialysis Transplantation, 2007, 22, 1323-1331.                          | 0.7 | 55        |
| 304 | Mutant mice provide new insight into the role of (mis-)glycation in IgA nephropathy and other glomerular diseases. Nephrology Dialysis Transplantation, 2007, 22, 1518-1520.                     | 0.7 | 3         |
| 305 | Treatment targets in renal fibrosis. Nephrology Dialysis Transplantation, 2007, 22, 3391-3407.   | 0.7 | 132       |
| 306 | Mesenchymal Stem Cells Prevent Progressive Experimental Renal Failure but Maldifferentiate into Glomerular Adipocytes. Journal of the American Society of Nephrology: JASN, 2007, 18, 1754-1764. | 6.1 | 265       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 307 | Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE). Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 898-905.   | 4.5 | 144       |
| 308 | The Role of PDGF-D in Mesangioproliferative Glomerulonephritis. , 2007, 157, 153-158.  |     | 12        |
| 309 | Role of T cells and dendritic cells in glomerular immunopathology. Seminars in Immunopathology, 2007, 29, 317-335.   | 6.1 | 57        |
| 310 | Genetic Heterogeneity in Italian Families with IgA Nephropathy: Suggestive Linkage for Two Novel IgA Nephropathy Loci. American Journal of Human Genetics, 2006, 79, 1130-1134.                                | 6.2 | 111       |
| 311 | Bone marrow transplantation rescues Alport mice*. Nephrology Dialysis Transplantation, 2006, 21, 2721-2723.  | 0.7 | 7         |
| 312 | Calcification and the usual suspect phosphate: still guilty but there are other guys behind the scenes. Nephrology Dialysis Transplantation, 2006, 21, 33-35.  | 0.7 | 15        |
| 313 | Study on the relationship of serum fetuin-A concentration with aortic stiffness in patients on dialysis. Nephrology Dialysis Transplantation, 2006, 21, 1293-1299.   | 0.7 | 82        |
| 314 | Is mycophenolate mofetil an effective treatment for persistent proteinuria in patients with IgA nephropathy?. Nature Clinical Practice Nephrology, 2006, 2, 16-17.   | 2.0 | 6         |
| 315 | Antagonism of PDGF-D by Human Antibody CR002 Prevents Renal Scarring in Experimental Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2006, 17, 1054-1062.                             | 6.1 | 64        |
| 316 | Calcification and Cardiovascular Health. Hypertension, 2006, 47, 1027-1034.  | 2.7 | 114       |
| 317 | Transplanted Mesenchymal Stem Cells Accelerate Glomerular Healing in Experimental Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2006, 17, 2202-2212.                                | 6.1 | 276       |
| 318 | R-roscovitine (CYC202) alleviates renal cell proliferation in nephritis without aggravating podocyte injury. Kidney International, 2005, 67, 1362-1370.  | 5.2 | 28        |
| 319 | ?Missing? inhibitors of calcification: general aspects and implications in renal failure. Pediatric Nephrology, 2005, 20, 383-388.   | 1.7 | 28        |
| 320 | An efficient system for tissue-specific overexpression of transgenes in podocytes in vivo. American Journal of Physiology - Renal Physiology, 2005, 289, F481-F488.  | 2.7 | 12        |
| 321 | Do not be misguided by guidelines: the calcium x phosphate product can be a Trojan horse. Nephrology Dialysis Transplantation, 2005, 20, 673-677.  | 0.7 | 36        |
| 322 | Identification and Functional Characterization of Dendritic Cells in the Healthy Murine Kidney and in Experimental Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2004, 15, 613-621. | 6.1 | 218       |
| 323 | Vascular calcification in patients with end-stage renal disease. Nephrology Dialysis Transplantation, 2004, 19, v59-v66.   | 0.7 | 166       |
| 324 | When man turns to stone: Extrasosseous calcification in uremic patients. Kidney International, 2004, 65, 2447-2462.  | 5.2 | 37        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 325 | Recurrent IgA nephropathy after renal transplantation. <i>Seminars in Nephrology</i> , 2004, 24, 287-291.  | 1.6  | 99        |
| 326 | Deficiencies of calcium-regulatory proteins in dialysis patients: A novel concept of cardiovascular calcification in uremia. <i>Kidney International</i> , 2003, 63, S84-S87.  | 5.2  | 99        |
| 327 | Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. <i>Lancet, The</i> , 2003, 361, 827-833.  | 13.7 | 822       |
| 328 | PDGF-C Expression in the Developing and Normal Adult Human Kidney and in Glomerular Diseases. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 1145-1153.  | 6.1  | 69        |
| 329 | Pathways to Recovery and Loss of Nephrons in Anti-Thy-1 Nephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 1904-1926.   | 6.1  | 73        |
| 330 | Evidence-based recommendations for immunosuppression in IgA nephropathy: handle with caution. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 241-245.  | 0.7  | 27        |
| 331 | Recurrent glomerulonephritis following renal transplantation: an update. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 1260-1265.   | 0.7  | 65        |
| 332 | The serum protein Î±2â€œHeremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. <i>Journal of Clinical Investigation</i> , 2003, 112, 357-366.  | 8.2  | 805       |
| 333 | Glomerular Remodelling: Novel Therapeutic Approaches Derived from the Apparently Chaotic Growth Factor Network. <i>Nephron</i> , 2002, 91, 582-587.  | 1.8  | 8         |
| 334 | Goto-Kakizaki rat is protected from proteinuria after induction of anti-Thy1 nephritis. <i>American Journal of Kidney Diseases</i> , 2002, 39, 985-1000.   | 1.9  | 8         |
| 335 | The Effects of Platelet-Derived Growth Factor Antagonism in Experimental Glomerulonephritis Are Independent of the Transforming Growth Factorâ€œÎ² System. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 658-667.                           | 6.1  | 46        |
| 336 | Expression of a Novel PDGF Isoform, PDGF-C, in Normal and Diseased Rat Kidney. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 910-917.   | 6.1  | 62        |
| 337 | Selective Cyclooxygenase-2 Inhibition Impairs Glomerular Capillary Healing in Experimental Glomerulonephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 1261-1270.   | 6.1  | 40        |
| 338 | Effects of Retinoids on the TGF-Î² System and Extracellular Matrix in Experimental Glomerulonephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 2300-2309.   | 6.1  | 57        |
| 339 | Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. <i>Kidney International</i> , 2000, 57, 167-182.  | 5.2  | 333       |
| 340 | IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 2395-2403.   | 6.1  | 161       |
| 341 | Early Mechanisms of Renal Injury in Hypercholesterolemic or Hypertriglyceridemic Rats. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 669-683.   | 6.1  | 159       |
| 342 | Augmentation of kidney injury by basic fibroblast growth factor or platelet-derived growth factor does not induce progressive diabetic nephropathy in the Goto Kakizaki model of non-insulin-dependent diabetes. <i>Translational Research</i> , 1999, 134, 304-312. | 2.3  | 28        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 343 | Novel Approach to Specific Growth Factor Inhibition in Vivo. American Journal of Pathology, 1999, 154, 169-179.   | 3.8 | 239       |
| 344 | VEGF165 mediates glomerular endothelial repair. Journal of Clinical Investigation, 1999, 104, 913-923.  | 8.2 | 268       |
| 345 | C-type natriuretic peptide inhibits mesangial cell proliferation and matrix accumulation in vivo. Kidney International, 1998, 53, 1143-1151.                            | 5.2 | 50        |
| 346 | Localization of PDGF $\alpha$ -receptor in the developing and mature human kidney. Kidney International, 1997, 51, 1140-1150.   | 5.2 | 48        |
| 347 | Age-related glomerulosclerosis and interstitial fibrosis in Milan normotensive rats: A podocyte disease. Kidney International, 1997, 51, 230-243.                       | 5.2 | 117       |
| 348 | Role of interleukin-6 in mediating mesangial cell proliferation and matrix production in vivo. Kidney International, 1997, 51, 69-78.                                   | 5.2 | 55        |
| 349 | Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney International, 1996, 49, 666-678.                             | 5.2 | 254       |
| 350 | Cellular events in the evolution of experimental diabetic nephropathy. Kidney International, 1995, 47, 935-944.   | 5.2 | 296       |
| 351 | Thrombospondin 1 is expressed by proliferating mesangial cells and is up-regulated by PDGF and bFGF in vivo. Kidney International, 1995, 48, 1846-1856.                 | 5.2 | 76        |
| 352 | Modulation of experimental mesangial proliferative nephritis by interferon- $\beta$ . Kidney International, 1995, 47, 62-69.  | 5.2 | 41        |
| 353 | Glomerular cells in vitro versus the glomerulus in vivo. Kidney International, 1994, 45, 360-368.   | 5.2 | 44        |
| 354 | Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis. Kidney International, 1993, 43, 369-380. | 5.2 | 149       |
| 355 | Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney International, 1992, 41, 297-309.                      | 5.2 | 369       |
| 356 | Altered glomerular extracellular matrix synthesis in experimental membranous nephropathy. Kidney International, 1992, 42, 573-585.                                      | 5.2 | 48        |
| 357 | Platelet-derived growth factor: A potentially important cytokine in glomerular disease. Kidney International, 1992, 41, 590-594.  | 5.2 | 52        |
| 358 | Regulation of Mesangial Cell Proliferation. American Journal of Kidney Diseases, 1991, 17, 673-676.   | 1.9 | 55        |
| 359 | Demonstration of PDGF B-chain mRNA in glomeruli in mesangial proliferative nephritis by in situ hybridization. Kidney International, 1991, 40, 470-476.                 | 5.2 | 103       |
| 360 | Increased synthesis of extracellular matrix in mesangial proliferative nephritis. Kidney International, 1991, 40, 477-488.  | 5.2 | 249       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 361 | Monokines and platelet-derived growth factor modulate prostanoid production in growth arrested, human mesangial cells. <i>Kidney International</i> , 1990, 37, 859-869. | 5.2 | 54        |